The Computable Molecule

Advanced Technology, Article, Artificial Intelligence, biotechnology, Book Chapter, Class Material, Science, , , ,

Artificial intelligence is no longer a tool that the life sciences industry is adopting. It is a force that is relocating where value is created and who captures it. Three costs are collapsing at once: drug discovery, company independence, and the ability to reach the patient. Each of these costs was, for forty years, a moat protecting the incumbents who could afford to pay it. In addition, the capacity to discover and manufacture medicine has become a strategic infrastructure in the same category as energy, semiconductors, and compute. The molecule has become computable. The architecture of value creation in life sciences has changed.

The AI Molecule

Advanced Technology, Article, Artificial Intelligence, biotechnology, Life Sciences, Science, Software, Transformative Businesses, , , , , , , , ,

Artificial intelligence is reducing the time and cost required to discover new drug candidates. New forms of late-stage capital are allowing better companies to stay independent longer. Direct-to-patient distribution is weakening Pharma’s control of the commercial channel. Together, these changes alter the architecture of biotechnology. The molecule is being separated from the old machine that used to deliver it. This is a structural change in how drugs are discovered, financed, developed, negotiated, and delivered. Biotech companies will build discovery systems, develop clinical evidence, control proprietary data, preserve financing options, and reach patients more directly.